Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 10/20 | 0.52 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.52 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | QDPR | P09417 | 3/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10345316 | 0.81 | TLR8 (0.48) | TLR8TLR7QDPR | |
| SCHEMBL15496639 | 0.80 | TLR8 (0.47) | TLR8TLR7QDPR | |
| SCHEMBL10325490 | 0.80 | TLR8 (0.59) | TLR8TLR7 | |
| SCHEMBL10325903 | 0.79 | TLR8 (0.58) | TLR8TLR7 | |
| SCHEMBL10345313 | 0.79 | TLR8 (0.67) | TLR8TLR7 | |
| SCHEMBL10345314 | 0.79 | TLR8 (0.57) | TLR8TLR7 | |
| SCHEMBL10345341 | 0.78 | TLR8 (0.45) | TLR8TLR7CCNT1CDK9QDPR | |
| SCHEMBL15496646 | 0.78 | TLR8 (0.56) | TLR8TLR7 | |
| SCHEMBL10326201 | 0.78 | TLR8 (0.56) | TLR8TLR7 | |
| SCHEMBL15496644 | 0.78 | TLR8 (0.64) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718796-B2 | Substituted benzoazepines as toll-like receptor modulators | VENTIRX PHARMACEUTICALS, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9718796-B2 | Substituted benzoazepines as toll-like receptor modulators | VENTIRX PHARMACEUTICALS, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| EP-2663550-B1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS INC (US) | 2016-12-14 | — | — | EP | disclosed |
| US-20140066432-A1 | Substituted Benzoazepines As Toll-Like Receptor Modulators | VENTIRX PHARMACEUTICALS, INC. | 2014-03-06 | — | — | US | disclosed |
| US-20140066432-A1 | Substituted Benzoazepines As Toll-Like Receptor Modulators | VENTIRX PHARMACEUTICALS, INC. | 2014-03-06 | — | — | US | disclosed |
| WO-2012097173-A2 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS, INC. (US) | 2012-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066432-A1 | Substituted Benzoazepines As Toll-Like Receptor Modulators | TLR8, TLR9, TLR1 | TLR8 1/4885TLR7 4/4885CCNT1 4653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.